JPMorgan BetaBuilders U.S. Small Cap Equity Fund (BBSC)
| Assets | $665.42M |
| Expense Ratio | 0.09% |
| PE Ratio | 18.61 |
| Shares Out | 8.48M |
| Dividend (ttm) | $0.84 |
| Dividend Yield | 1.07% |
| Ex-Dividend Date | Dec 23, 2025 |
| Payout Ratio | 19.82% |
| 1-Year Return | +19.77% |
| Volume | 42,828 |
| Open | 78.45 |
| Previous Close | 79.75 |
| Day's Range | 78.14 - 78.59 |
| 52-Week Low | 51.75 |
| 52-Week High | 81.04 |
| Beta | 1.16 |
| Holdings | 742 |
| Inception Date | Nov 16, 2020 |
About BBSC
Fund Home PageThe JPMorgan BetaBuilders U.S. Small Cap Equity Fund (BBSC) is an exchange-traded fund that mostly invests in small-cap stocks. The fund tracks a market-cap-weighted index of US small cap companies. BBSC was launched on Nov 16, 2020 and is issued by JPMorgan Chase.
Top 10 Holdings
5.56% of assets| Name | Symbol | Weight |
|---|---|---|
| JPMorgan U.S. Government Money Market Fund | MGMXX | 1.29% |
| TTM Technologies, Inc. | TTMI | 0.55% |
| Moog Inc. | MOG.A | 0.53% |
| CareTrust REIT, Inc. | CTRE | 0.48% |
| SiTime Corporation | SITM | 0.48% |
| American Healthcare REIT, Inc. | AHR | 0.48% |
| Primoris Services Corporation | PRIM | 0.45% |
| Semtech Corporation | SMTC | 0.44% |
| FormFactor, Inc. | FORM | 0.43% |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 0.43% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 23, 2025 | $0.30971 | Dec 26, 2025 |
| Sep 23, 2025 | $0.23767 | Sep 25, 2025 |
| Jun 24, 2025 | $0.17228 | Jun 26, 2025 |
| Mar 25, 2025 | $0.11649 | Mar 27, 2025 |
| Dec 24, 2024 | $0.3395 | Dec 27, 2024 |
| Sep 24, 2024 | $0.20494 | Sep 26, 2024 |
News
BBSC: Lagging Several Small-Cap Core ETFs
JPMorgan BetaBuilders U.S. Small Cap Equity ETF offers a very diversified portfolio with a low expense ratio. BBSC's heaviest sectors are financials, industrials, and healthcare. BBSC has underperform...
Why Is The IPO Market Struggling? Here's What Active Managers Have To Say
Strong returns in U.S. stocks, particularly over the past two plus years, have led investors to question the relative lack of companies going public via the IPO process — as well as the potential impl...
Tech IPOs Poised For Return To Pre-Pandemic Normalcy In 2025
The new year is poised for a resurgence in tech IPOs, as lower interest rates and an investor shift to small- and mid-cap companies combine to create a more welcoming market for debuts. The current en...
